Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer

被引:10
|
作者
Kramer, Gerbrand M. [1 ]
Yaqub, Maqsood [1 ]
Vargas, Herbert A. [2 ]
Schuit, Robert C. [1 ]
Windhorst, Albert D. [1 ]
van den Eertwegh, Alfonsus J. M. [3 ]
van der Veldt, Astrid A. M. [4 ,5 ,6 ,7 ]
Bergman, Andries M. [4 ]
Burnazi, Eva M. [2 ]
Lewis, Jason S. [2 ,8 ]
Chua, Sua [9 ]
Staton, Kevin D. [2 ]
Beattie, Brad J. [10 ]
Humm, John L. [10 ]
Davis, Ian D. [11 ,12 ]
Weickhardt, Andrew J. [13 ]
Scott, Andrew M. [13 ,14 ]
Morris, Michael J. [15 ,16 ]
Hoekstra, Otto S. [1 ]
Lammertsma, Adriaan A. [1 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Dept Radiol & Nucl Med, POB 7057, NL-1007 MB Amsterdam, Netherlands
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
[3] Vrije Univ Amsterdam, Amsterdam UMC, Dept Med Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
[6] Erasmus MC, Dept Radiol, Rotterdam, Netherlands
[7] Erasmus MC, Dept Nucl Med, Rotterdam, Netherlands
[8] Weill Cornell Med, Dept Radiol, New York, NY USA
[9] Royal Marsden NHS Fdn Trust, Dept Nucl Med, Sutton, Surrey, England
[10] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
[11] Monash Univ, Box Hill, Vic, Australia
[12] Eastern Hlth, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[13] Austin Hosp, Olivia Newton John Canc Res Inst, Dept Med Oncol, Melbourne, Vic, Australia
[14] Univ Melbourne, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[15] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[16] Weill Cornell Med, Dept Med, New York, NY USA
基金
英国医学研究理事会;
关键词
FDHT; PET/CT; prostate cancer; quantification; PET/CT; 16-BETA-F-18-FLUORO-5-ALPHA-DIHYDROTESTOSTERONE; REPEATABILITY; ENZALUTAMIDE;
D O I
10.2967/jnumed.118.220111
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-fluorodihydrotestosterone (F-18-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying F-18-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these F-18-FDHT uptake metrics. Methods: Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic F-18-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic O-15-H2O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUVBW), lean body mass (SUVLBM), whole blood (SUVWB), parent plasma activity concentration (SUVPP), area under the parent plasma curve (SUVAUC,PP), and area under the whole-blood input curve (SUVAUC,WB); and SUVBW corrected for sex hormone-binding globulin levels (SUVSHBG). Results were correlated with parameters derived from full pharmacokinetic F-18-FDHT and O-15-H2O. Finally, the repeatability of individual quantitative uptake metrics was assessed. Results: Eighty-seven F-18-FDHT-avid lesions were evaluated. F-18-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar K-i results (R-2 = 0.98). Patlak K-i and SUVAUC,PP showed an excellent correlation (R-2 > 0.9). SUVBW showed a moderate correlation to K-i (R-2 = 0.70, presumably due to fast F-18-FDHT metabolism. When calculating SUVSHBG, correlation to K-i improved (R-2 = 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients. 36% vs., 28%, respectively). F-18-FDHT uptake showed minimal blood flow dependency. Conclusion: F-18-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUVAUC, PP showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of F-18-FDHT uptake in whole-body PET/CT scans. In addition, SUVSHBG could potentially be used as an even simpler method to quantify F-18-FDHT uptake when less complex scanning protocols and accuracy are required.
引用
收藏
页码:1221 / 1227
页数:7
相关论文
共 50 条
  • [1] Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer
    Jansen, Bernard H. E.
    Yaqub, Maqsood
    Voortman, Jens
    Cysouw, Matthijs C. F.
    Windhorst, Albert D.
    Schuit, Robert C.
    Kramer, Gerbrand M.
    van den Eertwegh, Alfons J. M.
    Schwarte, Lothar A.
    Hendrikse, N. Harry
    Vis, Andre N.
    van Moorselaar, Reindert J. A.
    Hoekstra, Otto S.
    Boellaard, Ronald
    Oprea-Lager, Daniela E.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (12) : 1730 - 1735
  • [2] Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer
    Simoncic, Urban
    Perlman, Scott
    Liu, Glenn
    Jeraj, Robert
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (12) : 1174 - 1180
  • [3] 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide
    Ugo De Giorgi
    Paola Caroli
    Emanuela Scarpi
    Vincenza Conteduca
    Salvatore Luca Burgio
    Cecilia Menna
    Andrea Moretti
    Riccardo Galassi
    Lorena Rossi
    Dino Amadori
    Giovanni Paganelli
    Federica Matteucci
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1276 - 1283
  • [4] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [5] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [6] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05) : 558 - 567
  • [7] The changing landscape in metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 243 - 248
  • [8] Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers
    Maines, Francesca
    Caffo, Orazio
    Donner, Davide
    Sperduti, Isabella
    Bria, Emilio
    Veccia, Antonello
    Chierichetti, Franca
    Tortora, Giampaolo
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2016, 12 (03) : 333 - 342
  • [9] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [10] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2091 - 2102